Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 10/20 | 0.76 |
| ▸ | LTB4R2 | Q9NPC1 | 10/20 | 0.76 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9201426 | 0.94 | LTB4R (0.86) | LTB4RLTB4R2 | |
| SCHEMBL9199980 | 0.91 | LTB4R (0.66) | LTB4RLTB4R2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14021665 | 0.86 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL9203571 | 0.86 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL9201817 | 0.86 | LTB4R (0.77) | LTB4RLTB4R2 | |
| SCHEMBL9205433 | 0.83 | LTB4R (0.86) | LTB4RLTB4R2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9201444 | 0.82 | LTB4R (0.54) | LTB4RLTB4R2NPC1RAB9AMEN1 | |
| SCHEMBL9201451 | 0.82 | LTB4R (0.54) | LTB4RLTB4R2NPC1RAB9AMEN1 | |
| SCHEMBL9199491 | 0.82 | LTB4R (0.83) | LTB4RLTB4R2PPARAPPARG | |
| SCHEMBL9208352 | 0.79 | LTB4R (0.64) | LTB4RLTB4R2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0538416-B1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4 ANTAGONIST ACTIVITY | RHONE POULENC RORER INT (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0538416-A4 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY | RHONE POULENC RORER INT (US) | 1994-05-18 | — | — | EP | disclosed |
| US-5232948-A | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1993-08-03 | — | — | US | disclosed |
| EP-0538416-A1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY. | RHONE POULENC RORER INT (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992004315-A1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1992-03-19 | — | — | WO | disclosed |